The goal of the proposed project is to further develop antagen's novel protein nanoparticle-based expression and delivery system using fcrider technology and antibody afucosylation technology to…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00011
- Awardee
-
Antagen Biosciences Inc. UEI HXD6EFH2ND57
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,998
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · SBIRPHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $299,998.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Canton, MA 02021, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $299,998 |
About this award
Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, has been awarded a $299,998 firm fixed price Small Business Innovation Research (SBIR) contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Antagen will further develop its novel protein nanoparticle-based expression and delivery system using FcRider technology and antibody afucosylation technology to produce an engineered HIV envelope glycoprotein intended to induce broadly neutralizing antibodies against HIV. This award is set aside for total small business participation and supports the SBIR program's goals of stimulating technological innovation and strengthening the role of small businesses in meeting federal research and development needs.
Description
The goal of the proposed project is to further develop antagen's novel protein nanoparticle-based expression and delivery system using fcrider technology and antibody afucosylation technology to produce A2,6-sialylated afucosylated ENV-fcrider (
Quick answers
Who was awarded contract 75N93022C00011?
75N93022C00011 was awarded to Antagen Biosciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.
How much is contract 75N93022C00011 worth?
The government has obligated $299,998 on 75N93022C00011.
Was contract 75N93022C00011 competed?
The extent of competition for 75N93022C00011 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award